Encapsulated Live Cell Market

Live cell encapsulation has long been proposed as a solution in modern medicine to many therapeutic problems. Cell encapsulation technology is used for the immobilization of cells within biocompatible and semipermeable membranes. The encapsulation of cells, instead of therapeutic products, is used to allow the delivery of molecules of interest for a longer time period as cells release these molecules of interest continuously. Furthermore, cells can be engineered for expressing the protein of interest in vivo without modifying the hosts genome. Cell encapsulation presents a significant advantage compared to protein encapsulation, as cell encapsulation allows a sustained and controlled delivery therapeutic molecules at a constant rate, thereby resulting in greater physiological concentrations.

Encapsulated Live Cell Market contains market size and forecasts of Encapsulated Live Cell in Global, including the following market information:

• Global Encapsulated Live Cell Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global top five companies in 2021 (%)

The global Encapsulated Live Cell market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Alginate Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Encapsulated Live Cell include Viacyte, Inc., Living Cell Technologies Ltd., Sigilon Therapeutics, Inc, Sernova Corporation, PharmaCyte Biotech Inc, Gloriana Therapeutics, Kadimastem, Beta-O2 Technologies, Inc. and Altucell, Inc. and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Encapsulated Live Cell companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Encapsulated Live Cell Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Encapsulated Live Cell Market Segment Percentages, by Type, 2021 (%)

• Alginate
• Chitosan
• Cellulose
• Others

Global Encapsulated Live Cell Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Encapsulated Live Cell Market Segment Percentages, by Application, 2021 (%)

• Diabetes
• Cancer
• Epilepsy
• Parkinson
• Others

Global Encapsulated Live Cell Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Encapsulated Live Cell Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Encapsulated Live Cell revenues in global market, 2017-2022 (estimated), ($ millions)
• Key companies Encapsulated Live Cell revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Viacyte, Inc.
• Living Cell Technologies Ltd.
• Sigilon Therapeutics, Inc
• Sernova Corporation
• PharmaCyte Biotech Inc
• Gloriana Therapeutics
• Kadimastem
• Beta-O2 Technologies, Inc.
• Altucell, Inc.
• Diatranz Otsuka Ltd